Transkaryotic Ex-CEO Settles SEC Suit For $1.2M
The former chief executive officer of Transkaryotic Therapies Inc. has agreed to pay $1.2 million to settle allegations by the U.S. Securities and Exchange Commission that he concealed the failure of...To view the full article, register now.
Already a subscriber? Click here to view full article